Project 2 - Cell of origin contributions and vulnerabilities in clonal hematopoiesis

$488,196P01FY2025HLNIH

Massachusetts General Hospital, Boston MA

Investigators

Linked publications, trials & patents

Paper 39487555 Paper 39483908 Paper 39345504 Paper 38939973 Paper 38773071 Paper 38546390 Paper 38345255 Paper 38160994 Paper 37668919 Paper 37501279 Paper 37428871 Paper 37267513 Paper 37209097 Paper 37126722 Paper 37119815 Paper 36593155 Paper 36384171 Paper 36382886 Paper 36269860 Paper 36227997 Paper 36137040 Paper 36104445 Paper 36010677 Paper 35613022 Paper 35551192 Paper 35427766 Paper 35411071 Paper 35263572 Paper 34965583 Paper 34939923 Paper 34857894 Paper 34854833 Paper 34735227 Paper 34593523 Paper 34573282 Paper 34348892 Paper 34242616 Paper 34120146 Paper 34114603 Paper 34078745 Paper 34010414 Paper 33986176 Paper 33971010 Paper 33914855 Paper 33884376 Paper 33854168 Paper 33821975 Paper 33770508 Paper 33747521 Paper 33741760 Paper 33649590 Paper 33633351 Paper 33621486 Paper 33547048 Paper 33444684 Paper 33406418 Paper 33397967 Paper 33264224 Paper 33087503 Paper 32966797 Paper 32883883 Paper 32822472 Paper 32770691 Paper 32749922 Paper 32669716 Paper 32589959 Paper 32542325 Paper 32413320 Paper 32345594 Paper 32302558 Paper 32259481 Paper 32194831 Paper 32045462 Paper 32025033 Paper 32004478 Paper 31974159 Paper 31836582 Paper 31780633 Paper 31625720 Paper 31291568 Paper 30979687 Paper 30485801 Paper 30425071 Paper 30266803 Paper 30139917 Paper 30081475 Paper 29899448 Paper 29739946 Paper 29654272 Paper 29323290 Paper 28900037 Paper 27488898 Paper 27373511 Patent 12193996

Abstract

Project Summary Heterogeneity within the hematopoietic stem cell (HSC) compartment is well defined and we hypothesize may contribute to the wide range of phenotypes emerging from initiation of clonal hematopoiesis (CH). This project will use distinctive tools for assessing cell state in the context of Tet2 deletion to determine how the epigenetic and transcriptional program of the cell of origin affects clonal dominance. These data will provide insight into the mechanisms of clonal dominance and may offer epigenetic signatures indicative of risk for subsequent validation. We will also focus on the metabolic state of dominant CH to define whether features of those cells render them vulnerable to low intensity intervention. Successful accomplishment will guide strategies for selective depletion of aberrant dominant clones.

View original record on NIH RePORTER →